<DOC>
	<DOC>NCT02153437</DOC>
	<brief_summary>To determine the effect of our compound (BMS-919373) on electrical activity of the heart using pacemakers.</brief_summary>
	<brief_title>Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Sotalol</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Age 18 years to 85 years Eligible patients will have a dualchamber permanent pacemaker Women who are not of childbearing potential Patients with a history of Atrial Fibrillation (AF) that is either (i) Permanent (i.e. patients are only in AF and never in sinus rhythm) or (ii) Persistent (i.e. patients who's episodes of AF are longer than 7 days and require medical intervention, such as electrical or medical cardioversion, to return to sinus rhythm), are excluded History of Transient Ischemic Attack (TIA) or stroke in the last 12 months History of clinically significant ventricular arrhythmia (not including isolated monomorphic Premature Ventricular Contractions (PVCs)). Such arrhythmias are marked by loss of consciousness, emergent cardioversion or defibrillation or unstable vital signs requiring medical intervention Complete heart block Planned surgery, endovascular intervention or cardioversion within the study period History of atrial fibrillation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>